The Most Expensive Mistakes in Biotech Are Often Regulatory, Not Scientific

Regulatory Strategy for Emerging Biotech and Pharma

How earlier regulatory decisions can reduce development uncertainty, protect capital, strengthen CMC readiness, and improve the path to critical clinical, financing, partnering, and approval milestones.

Over the years, there has been a recurring pattern in emerging biotech and pharma companies. When development timelines slip, management teams often point to science, clinical execution, or manufacturing as the root cause. However, many of the costliest delays can be traced back to decisions made much earlier in development, before an IND, CTA, or marketing authorization application is submitted.

In my opinion, the biggest risk facing early-stage biotech and pharma companies is not necessarily scientific failure; it is regulatory uncertainty translating into suboptimal development decisions.

For investor-backed biotech and pharma, these decisions have real consequences:

• Increased burn rate
• Additional financing requirements
• Delayed value-inflection points
• Reduced partnering opportunities
• Lower probability of approval

The irony is that many of these risks are preventable. Below are some common pitfalls and how to address them:

Treating Regulatory Affairs as a Submission Function

Many companies still engage in Regulatory Affairs primarily as a documentation and submission resource. The reality is that Regulatory Affairs should influence development strategy from the moment a candidate enters development.

A strong regulatory strategy helps answer questions such as:

• What is the most efficient approval pathway?
• What evidence will regulators expect?
• What are the critical risks?
• How should clinical, nonclinical, and CMC activities be sequenced?
• How can we maximize opportunities for expedited pathways?

By the time an IND is being assembled, many of the most important strategic questions have already been answered, and regulatory input after those decisions is often too late.

Underestimating the Importance of Early Agency Alignment

Many emerging biotech and pharma companies believe they can “figure out the regulatory details later.”

Unfortunately, regulators may have a different view of:

• Patient populations
• Clinical endpoints
• Trial design
• Statistical considerations
• CMC expectations

When development plans evolve without sufficient regulatory alignment, the result can be:

• Additional studies
• Protocol amendments
• Delayed timelines
• Increased costs

Every additional study can translate into months or years of delay and millions of dollars in additional development spending. For venture-backed organizations operating within a limited runway, those delays can become existential.

Missing Opportunities for Expedited Pathways

One of the most overlooked areas of value creation is expediting regulatory pathways.

Too many companies view designations such as Orphan Drug Designation, Fast Track, Breakthrough Therapy, PRIME, etc., as regulatory milestones rather than strategic assets.

These programs can influence the frequency of agency interactions, development timelines, investor perception, and partnering attractiveness—all coming together in commercial value.

The most successful development programs often integrate expedited pathway planning into their overall development strategy from the beginning. The question should not be: “Can we apply for a designation?” Instead, it should be: “How do we design our development program to maximize eligibility for accelerated pathways?”

Waiting Too Long to Address CMC Strategy

Perhaps the most common source of avoidable delays is CMC readiness. Many organizations devote tremendous attention to clinical data while treating manufacturing and CMC as downstream activities. Unfortunately, regulatory agencies do see CMC as an integral part of the submissions.

I have seen programs with promising clinical outcomes slowed by:

• Manufacturing readiness gaps
• CMC documentation deficiencies
• Process validation issues
• Inspection findings
• Supply chain challenges

A successful approval package is only as strong as its weakest component. The earlier CMC strategy is integrated into development planning, the lower the likelihood of costly surprises later.

Thinking Only About Approval

This may be the most important pitfall of all. Regulatory success does not automatically translate into business success. Companies sometimes focus exclusively on obtaining approval while overlooking broader questions:

• Will the evidence support reimbursement?
• Will the label support commercial adoption?
• Will the development strategy attract partners?
• Will investors view the path as credible and scalable?

The best regulatory strategy goes beyond approval and uses a comprehensive target profile. It focuses on enterprise value.

Failing to Connect Regulatory Decisions to Runway

Every biotech and pharma executive understands the cash runway. Far fewer organizations connect regulatory strategy directly to capital efficiency. A poorly designed development program can lead to:

• Additional studies
• Delayed milestones
• Increased operational costs
• Additional funding rounds
• Greater shareholder dilution

Conversely, better regulatory decisions can preserve significant amounts of capital by reducing uncertainty and avoiding rework. This is why you should view Regulatory Affairs as a capital allocation function as much as a compliance function.

The Future of Regulatory Affairs

The industry is changing.

Regulatory Affairs is evolving more into a strategic intelligence function. The organizations creating the most value are combining regulatory expertise, development strategy, competitive intelligence, AI-enabled insights, and proactive risk management.

The goal is not simply to submit applications. The goal is to make better development decisions earlier.

For emerging biotech and pharma companies, the most valuable contribution Regulatory Affairs can make is not preparing an IND, CTA, NDA, BLA, or MAA. It is helping management teams answer a much more important question: What decisions should we make today to maximize the probability of reaching our next financing, clinical, partnering, and approval milestone?

The companies that answer that question well are often the ones that preserve runway, accelerate development, and create the greatest value for patients, investors, and shareholders alike.

Make Regulatory Strategy an Earlier Development Decision

For emerging biotech and pharma companies, regulatory strategies should begin well before submission preparation. Early alignment across regulatory, clinical, nonclinical, and CMC activities can help identify development risks sooner, reduce avoidable rework, and create a clearer path toward key regulatory and business milestones.

Celegence works with pharmaceutical and biotech organizations across regulatory strategy, agency interactions, CMC, regulatory intelligence, medical writing, publishing and submissions, and lifecycle management, helping teams translate complex regulatory requirements into practical development plans.

Talk to Our Regulatory Experts →